Health TrialsbyHealthPanel

Non-invasive Monitoring of Miscarriage

ConditionMiscarriage in First Trimester
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-45
SponsorChinese University of Hong Kong

About this trial

cfDNA is extremely useful to ascertain chromosomal causes of miscarriages at the point of miscarriage diagnosis by a simple blood test. This study aims to determine the level of cell-free DNA (cfDNA) in early pregnancy and compare the results with those of product of conception (POC) testing, in concordance with standard karyotyping.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-45 years.

Women who attend the early pregnancy loss clinic or Patients who receive ART

Their partner, the biological father of the pregnancy

Disqualifiers

History of psychological/ psychiatric problem

Patient refusal

Trial population

Patients will be approached on the day of attending the early pregnancy loss clinic, and given information about the study. Sufficient time will be allowed for consideration before they confirm their decision and sign the consent. For cases with the management of ultrasound-guided manual vacuum aspiration (USG-MVA) or surgical evacuation, their remaining products of gestation will be collected for analysis.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • This is a routine procedure, no intervention will be provided.

    Other intervention

    This is a routine procedure, no intervention will be provided.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Cell-free DNA (cfDNA)

Determine the use of cfDNA to ascertain chromosomal causes of miscarriages

Time frame
15 weeks

Secondary outcomes

1

Level of cell-free DNA

To determine the level of cell-free DNA (cfDNA) in early pregnancy

Time frame
15 weeks
2

Aneuploidy results from product of conception

To compare the aneuploidy results from product of conception (POC), in concordance with standard karyotyping.

Time frame
15 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese University of Hong Kong

Lead sponsor

Source ClinicalTrials.gov
Apply now